S
Sollis Therapeutics
Privately held pharmaceutical company developing non-opioid analgesic solutions
About Sollis Therapeutics
Sollis Therapeutics is a healthcare startup that is focused on developing innovative treatments for sciatica pain. The company is currently working on an investigational therapy for patients who have not found relief from traditional sciatica pain treatments. Their primary product in development is the Clonidine Micropellet, a non-opioid, non-steroid medication designed to target the source of sciatica pain over time and reduce inflammation at the injured nerve.
The company operates in the healthcare and pharmaceutical market, specifically focusing on pain management. Their target clients are primarily patients suffering from sciatica pain, as well as clinicians seeking new interventions for treating this condition.
Sollis Therapeutics' business model revolves around the research, development, and eventual commercialization of their investigational therapy. The company is currently in the process of enrolling patients for their Phase 3 SERENITY CM study, which will provide further clinical evidence for the effectiveness of their treatment. Once the product has been thoroughly tested and approved, the company will generate revenue through the sale of the Clonidine Micropellet to healthcare providers and patients.
In summary, Sollis Therapeutics is a promising startup that is working to redefine the treatment of sciatica pain with a new, non-opioid, non-steroid medication. Their innovative approach could potentially provide a much-needed solution for patients who have not found relief from traditional treatments.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Columbus, United States
- Employees
- 27
- Open positions
- None listed
- Dealroom signal
- 67.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Rehabilitation, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Apr 2018 | $50M | $200M | Deerfield | — |
Growth signals
Latest recorded traffic for Sollis Therapeutics is 150 monthly website visits, down 21.1% over the last three months. Sollis Therapeutics's team declined 3.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Sollis Therapeutics in the Columbus ecosystem
The Sollis Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Deerfield
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sollis Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sollis Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










